Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.

Anthony P Carnicelli Sana M Al-KhatibDenis XavierFrederik DalgaardPeter D MerrillDaniel M WojdylaBasil S LewisMichael HannaJohn H AlexanderRenato Deláscio LopesLars WallentinChristopher B Granger

Published in: Heart (British Cardiac Society) (2020)

Premature permanent discontinuation of study drug in ARISTOTLE was common, less frequent in patients receiving apixaban than warfarin and was followed by high 30-day rates of death, thromboembolism and major bleeding. Initiatives are needed to reduce discontinuation of oral anticoagulation.

Keyphrases

atrial fibrillation
venous thromboembolism
direct oral anticoagulants
oral anticoagulants
quality improvement
emergency department
adverse drug